🇮🇱 Hu3F8 in Israel

Hu3F8 (NAXITAMAB) regulatory status in Israel.

Marketing authorisation

MOH

  • Status: likely_approved

Hu3F8 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in Israel

Frequently asked questions

Is Hu3F8 approved in Israel?

Yes. MOH has authorised it.

Who is the marketing authorisation holder for Hu3F8 in Israel?

Y-Mabs Therapeutics Inc is the originator. The local marketing authorisation holder may differ — check the official source linked above.